论文部分内容阅读
肝纤维化指肝内结缔组织异常增生,包括细胞、纤维与基质,但以胶原纤维增生更为突出。其研究经过形态学描述和生理生化学研究阶段,现已进入分子生物学研究阶段。从分子水平研究肝纤维化治疗已获某些令人鼓舞的初步结果,其理论基础是抑制胶原合成,促进胶原降解和吸收,达到抗肝纤维化的目的。胶原合成包括:DNA转录、mRNA翻译合成α-肽链,经羟化、糖基化和3条肽链拧成螺旋状前胶原,通过微管分泌到细胞外,再经裂解、氧化、缩合和交联而成胶原纤维。本文就近2年来,对抗肝纤维化实验与临床研究进展作扼要介绍。
Liver fibrosis refers to the abnormal proliferation of connective tissue in the liver, including cells, fibers and matrix, but more prominent collagen fibers. After the study of morphological description and physiological and biochemical research phase, has now entered the molecular biology phase. At the molecular level, there have been some encouraging initial results in the treatment of liver fibrosis. The theoretical basis is to inhibit collagen synthesis, promote collagen degradation and absorption, and achieve anti-hepatic fibrosis. Collagen synthesis includes: DNA transcription, mRNA translation and synthesis of α-peptide chain, hydroxylation, glycosylation and three peptide chains into spiral pre-collagen, secreted by the microtubules to the cell, and then by cracking, oxidation, condensation and Crosslinked collagen fibers. This article in the recent 2 years, against liver fibrosis experiments and clinical research for a brief introduction.